News

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living ...
pharmaphorum5d
GSK gets wide FDA approval for myelofibrosis drug
Now given the trade name Ojjaara, GSK's once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor can be given as an alternative to other JAK inhibitors in the first-line setting ...
Nasdaq4d
iBio, Inc. Enters Licensing Agreement with AstralBio for First-in-Class Activin E-Targeting Antibody to Address Obesity and Cardiometabolic Diseases
The in-licensed antibody represents what iBio believes to be the first functional inhibitor of Activin E, a challenging, yet genetically validated therapeutic target playing a key role in ...
Medpage Today on MSN3mon
Have the New Pulmonary Hypertension Drugs Changed the Game?
Its approval this year as the first activin-signaling inhibitor for PAH -- indicated to increase exercise capacity, improve ...
Hosted on MSN4mon
Takeda licensed for anaemia therapy by Keros Therapeutics
Takeda has agreed to receive an exclusive global licence from Keros Therapeutics to advance the development, manufacture and commercialisation of the investigational activin inhibitor elritercept ...
Healio27d
Trial supports sotatercept as standard of care for high-risk patients with PAH
The trial was halted early due to positive efficacy data. CHICAGO — Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary ...
technologynetworks1y
Cytokines for Stem Cell Research: Activin A, OSM, EGF and More
Cytokines like Activin A/INHBA, OSM, EGF, VEGFA, IL3, LIF, and FGF2 play integral roles in stem and progenitor cell research. For example, OSM has been used in combination with HGF, EGF, LIF, and FGF2 ...